Americana Partners LLC Has $5.59 Million Stock Holdings in Amgen Inc. $AMGN

Americana Partners LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 31.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,085 shares of the medical research company’s stock after buying an additional 4,081 shares during the quarter. Americana Partners LLC’s holdings in Amgen were worth $5,592,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Robeco Institutional Asset Management B.V. boosted its holdings in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC bought a new position in Amgen during the fourth quarter worth about $1,669,000. Jones Financial Companies Lllp boosted its holdings in Amgen by 18.2% during the third quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after buying an additional 6,115 shares during the last quarter. Adell Harriman & Carpenter Inc. boosted its holdings in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after buying an additional 1,609 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Amgen by 8.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 591,891 shares of the medical research company’s stock worth $167,032,000 after buying an additional 47,958 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AMGN shares. TD Cowen restated a “buy” rating on shares of Amgen in a report on Wednesday, February 4th. Cantor Fitzgerald restated a “neutral” rating and set a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Rothschild & Co Redburn raised their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Guggenheim reduced their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Finally, Truist Financial raised their target price on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $355.19.

Amgen Stock Up 0.6%

AMGN stock opened at $339.30 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $183.11 billion, a PE ratio of 23.61, a PEG ratio of 3.39 and a beta of 0.44. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The business’s 50 day simple moving average is $345.10 and its 200 day simple moving average is $344.38.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts anticipate that Amgen Inc. will post 22.37 EPS for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.0%. Amgen’s payout ratio is 70.15%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.